GO
Loading...

Pharmaceuticals

More

  • Merck, SGP Go On A Vytorin "Offensive" Tuesday, 22 Jan 2008 | 11:22 AM ET

    I'm blogging today from outside the New York Stock Exchange where I'm trying to round up "man-on-the-(Wall) street" reaction to the markets. In the meantime, back on the beat, for the second day Merck and Schering-Plough have taken out two-page ads in major newspapers defending their cholesterol drugs Zetia and Vytorin whose efficacy is under attack.

  • Roche Wins Ventana with Raised $3.4 Billion Bid Tuesday, 22 Jan 2008 | 3:31 AM ET

    Roche Holding has overcome Ventana's resistance to its takeover bid by raising its price, acquiring the diagnostics maker for $3.4 billion to boost its cancer testing business.

  • Dendreon's Provenge: No Congressional Decision-YET Friday, 18 Jan 2008 | 4:04 PM ET

    I blogged recently that a spokesperson for the House Energy and Commerce Committee had told me a decision could be made by the end of this week regarding the Dendreon saga.

  • SGP's CEO Hassan: Putting Money Where His Mouth Is Friday, 18 Jan 2008 | 12:58 PM ET

    After watching his stock lose more than one-fifth of its value this week, Schering-Plough CEO Fred Hassan apparently decided the shares are on sale. This morning the company issued a press release announcing Hassan (pronounced Haa-sun, not the commonly mispronounced Huh-sahn) will shell out $2 million of his own money to buy SGP shares on the open market.

  • Pfizer's Chantix Warning: Hazardous To Mental Health? Friday, 18 Jan 2008 | 10:35 AM ET

    This doesn't come as any big surprise, but Pfizer announced this morning that it is putting a warning--and that's the company's word--on the label of its stop-smoking pill Chantix. It says people taking the drug should be watched for "serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior."

  • Macke: Playing Defense Thursday, 17 Jan 2008 | 4:48 PM ET

    Playing defense is the best thing to do right now, Jeff says. Don't pick a bottom yet.

  • Euro Stocks End Lower on US Economy Fears Thursday, 17 Jan 2008 | 12:44 PM ET

    Europe's major indexes closed lower across the board Thursday despite assurances from Federal Reserve Chairman Ben Bernanke that he would act agressively to counter the risks of a U.S. recession.

  • Pharma Investors: Will Political Talk Scare Them Off? Thursday, 17 Jan 2008 | 10:32 AM ET

    If or when you watch one of the presidential  debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...

  • Merck, Schering in Vytorin Victory Wednesday, 16 Jan 2008 | 12:40 PM ET

    The American College of Cardiology is weighing in on the controversial ENHANCE study that has battered shares of Merck and Schering-Plough over the past couple of days. Most notably I think is that the ACC says, "There should be no reason for patients to panic."

  • EU Raids Drug Companies in Broad Inquiry Wednesday, 16 Jan 2008 | 10:20 AM ET

    The European Commission raided some of the world's largest drugmakers on Wednesday, launching a broad investigation into whether they made illegal deals or abused patents to limit competition and harm consumers.

  • Sudden Death: Puget Energy, Teva Pharma and More Tuesday, 15 Jan 2008 | 8:29 PM ET

    It's a booyah-free zone. There goes Swifty!Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Lightning Round: Loews, NYSE, Tesco and More Tuesday, 15 Jan 2008 | 3:39 PM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Outsourcing Is Good – for Investors Tuesday, 15 Jan 2008 | 3:37 PM ET

    To politicians, railing against it brings votes. To companies, it cuts costs. But to Cramer, it’s a chance to make Homegamers some mad money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Are Herbal Remedies the New Big Pharma? Tuesday, 15 Jan 2008 | 12:18 PM ET

    Big pharma is heralded for inventing new cures, but the courts are clogged with dangerous drug cases. Most of the world has used plant-based remedies for hundreds if not thousands of years. Here, there's plenty of skepticism, but Chris Kilham, professor of ethnobotany and explorer in residence at the University of Massachusetts, says herbal medicines are much safer than synthetic drugs.

  • Pfizer's Chantix Is "Smokin'" Again Tuesday, 15 Jan 2008 | 10:52 AM ET

    I had planned to blog about the nearly unanimous bearish analyst commentary this morning after Genentech's earnings report yesterday. The biotech giant beat on earnings per share, but came up short on Street expectations for sales of its top four drugs. DNA shares are under pressure again today.

  • Novo Nordisk: A Big "No" To Inhaled Insulin--For Now Tuesday, 15 Jan 2008 | 8:11 AM ET

    In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.

  • Genetech

    Genentech reported a profit that rose 6.4 percent and beat forecasts, but sales of all four of the company's main drugs fell short of expectations.

  • Merck And Schering Plough: "Enhancing" A Franchise? Monday, 14 Jan 2008 | 2:13 PM ET

    The highly anticipated results of the study that goes by the acronym "ENHANCE" are out this morning. You can see what it stands for in the companies' press release. (I wonder how many meetings and brainstorming sessions go into coming up with some of the industry's clinical trial acronyms and abbreviations.)

  • Merck, Schering: Cholesteral Drug Study Disappoints Monday, 14 Jan 2008 | 10:50 AM ET

    Merck and Schering-Plough said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.

  • Dendreon's Saga Over Provenge "Edited Up" A Notch Friday, 11 Jan 2008 | 1:09 PM ET

    The brouhaha over the Food and Drug Administration's delay of the potential approval of the prostate cancer drug Provenge from the small biotechnology company Dendreon is now entering the prestigious and credible sphere of peer-reviewed scientific journals.